Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities (Tables)

v3.21.2
Accrued Expenses and Other Liabilities (Tables)
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued Expenses, summarized by major category, as of June 30, 2021 and December 31, 2020 consist of the following:

 

    June 30, 2021     December 31, 2020  
Payroll and incentives   $ 619     $ 1,094  
General and administrative expenses     249       280  
Research and development expenses     1,055       778  
Deferred revenue and other deferred liabilities *     840       643  
Total   $ 2,763     $ 2,795  

 

* At June 30, 2021, there was an approximately $807 thousand deferred liability under the Cystic Fibrosis Foundation (“CFF”) agreement and approximately $33 thousand in deferred revenue related to the Genentech Agreement. At December 31, 2020, there was an approximately $577 thousand deferred liability under the CFF Agreement and approximately $67 thousand in deferred revenue related to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).